On behalf of the more than 1,200 members of the Biotechnology Industry Organization (BIO), I am writing to express concerns with SB 2863 "An Act to Control Cost Containment, Transparency and Efficiency in the Delivery of Quality Health Care." This legislation, currently pending your approval, contains provisions in Section 14 of the bill that could have serious unintended consequences on the Commonwealth's biotechnology industry.
As one of the world's leading medical centers and biotechnology industry hubs, we acknowledge the need for Massachusetts to be at the forefront of implementing policies to improve health care. In addition to the Life Science Initiative, the Commonwealth Care Program is an example of a progressive effort to address a concern affecting many states - creating access to affordable health insurance for all citizens. These programs have become national models and send a clear message that Massachusetts is serious about promoting life science innovation and improving access to quality health care.
BIO and BIO members are urging lawmakers to enact a short-term extension of the MCM-PRV program while Congress is waiting to address a full reauthorization with PAHPA.
BIO has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
BIO and 24 other organizations call on the Biden Administration to discuss supply chains and food security in future High-Level Economic Dialogue meetings.
RE: Concerns with Senate Bill 2863
Dear Governor Patrick,
On behalf of the more than 1,200 members of the Biotechnology Industry Organization (BIO), I am writing to express concerns with SB 2863 "An Act to Control Cost Containment, Transparency and Efficiency in the Delivery of Quality Health Care." This legislation, currently pending your approval, contains provisions in Section 14 of the bill that could have serious unintended consequences on the Commonwealth's biotechnology industry.
As one of the world's leading medical centers and biotechnology industry hubs, we acknowledge the need for Massachusetts to be at the forefront of implementing policies to improve health care. In addition to the Life Science Initiative, the Commonwealth Care Program is an example of a progressive effort to address a concern affecting many states - creating access to affordable health insurance for all citizens. These programs have become national models and send a clear message that Massachusetts is serious about promoting life science innovation and improving access to quality health care.